...
首页> 外文期刊>Neuroradiology >Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
【24h】

Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.

机译:在早期无反应性静脉内组织纤溶酶原激活剂治疗后,对超急性MCA缺血性中风患者进行局部动脉内溶栓治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

The outcome of patients who show no early response to intravenous (i.v.) tissue plasminogen activator (tPA) therapy is poor. The objective of this study was to evaluate the feasibility of rescue localized intra-arterial thrombolysis (LIT) therapy for acute ischemic stroke patients after an early non-responsive i.v. tPA therapy. Patients with proximal MCA occlusions who were treated by LIT (n = 10) after failure of early response [no improvement or improvement of National Institute of Health Stroke Scale (NIHSS) scores of < or = 3] to i.v. tPA therapy (0.9 mg/kg-10% bolus and 90% i.v. infusion over 60 min) were selected. The recanalization rates, incidence of post-thrombolysis hemorrhage and clinical outcomes [baseline and discharge NIHSS scores, mortality, 3 months Barthel index (BI) and modified Rankin score (mRS)] were evaluated. Rescue LIT therapy was performed on ten MCA occlusion patients (male:female = 3:7, mean age 71 years). The mean time between the initiation of i.v. tPA therapy and the initiation of intra-arterial urokinase (i.a. UK) was 117+/-25.0 min [time to i.v. tPA 137+/-32 min; time to digital subtraction angiography (DSA) 221+/-42 min; time to i.a. UK 260+/-46 min]. The baseline NIHSS scores showed significant improvement at discharge (median from 18 to 6). Symptomatic hemorrhage and, consequent, mortality were noted in 2/10 (20%) patients. Three months good outcome was noted in 4/10 (40%, mRS 0-2) and 3/10 (30%, BI > or = 95). In conclusion, rescue LIT therapy can be considered as a treatment option for patients not showing early response to full dose i.v. tPA therapy. Larger scale studies for further validation of this protocol may be necessary.
机译:对静脉内(i.v.)组织纤溶酶原激活剂(tPA)治疗无早期反应的患者的预后很差。这项研究的目的是评估早期无反应静脉内注射后对急性缺血性中风患者进行局部局部溶栓(LIT)抢救的可行性。 tPA治疗。早期反应失败[无改善或国立卫生研究院卒中量表(NIHSS)评分<或= 3的改善或改善]后接受LIT(n = 10)治疗的近端MCA闭塞患者。选择tPA疗法(在60分钟内推注0.9 mg / kg-10%的推注和90%的静脉输注)。评估了再通率,溶栓后出血的发生率和临床结局[基线和出院NIHSS评分,死亡率,3个月Barthel指数(BI)和改良的Rankin评分(mRS)]。对十名MCA闭塞患者(男性:女性= 3:7,平均年龄71岁)进行了挽救性LIT治疗。开始i.v. tPA治疗和动脉内尿激酶(英国)的启动时间为117 +/- 25.0分钟tPA 137 +/- 32分钟;数字减影血管造影(DSA)时间221 +/- 42分钟;时间到英国260 +/- 46分钟]。基线NIHSS评分显示出院时有明显改善(中位数从18到6)。在2/10(20%)的患者中发现了症状性出血和相应的死亡率。三个月中,4/10(40%,mRS 0-2)和3/10(30%,BI>或= 95)观察到良好的预后。总之,对于未对全剂量静脉内注射显示早期反应的患者,可以考虑采用抢救性LIT治疗。 tPA治疗。为了进一步验证此协议,可能需要进行大规模研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号